For eligible previously treated adults with HER2-low (IHC 1+ or IHC 2+/ISH–) mBC1

NCCN GUIDELINES® PREFERRED

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Preferred

CATEGORY 1, Preferred Systemic Therapy Regimen
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommends fam-trastuzumab deruxtecan-nxki (ENHERTU) as a Category 1, preferred second-line systemic therapy option for recurrent unresectable (local or regional) or stage IV HER2-negative breast cancer in2,a:

  • Patients with HR+ disease who are in visceral crisis or are endocrine refractory with tumors that are HER2 IHC 1+ or 2+ and ISH negative
  • Patients with HR– disease who have tumors that are HER2 IHC 1+ or 2+ and ISH negative with no germline BRCA1/2 mutation

aFam-trastuzumab deruxtecan-nxki may be considered in a later line if not used in second line.2

BRCA1/2, BReast CAncer gene 1 or 2; HER2, human epidermal growth factor receptor 2; HR–, hormone receptor-negative; HR+, hormone receptor-positive; IHC, immunohistochemistry; ISH, in situ hybridization; mBC, metastatic breast cancer; NCCN, National Comprehensive Cancer Network® (NCCN®).